Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Expression Analysis in CLL/SLL Treated with Rituximab and Fludarabine
NCT00001586Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 1997
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and fludarabine in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Change in Gene Expression Post Chemo at 24 hours. Started Sep 1997; status: completed.
02
Drugs
rituximabfludarabine
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00001586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001586.